Johnson Shelsey W, Garcia Michael A, Sisson Emily K Q, Sheldrick Christopher R, Kumar Vishakha K, Boman Karen, Bolesta Scott, Bansal Vikas, Lal Amos, Domecq J P, Melamed Roman R, Christie Amy B, Husain Abdurrahman, Yus Santiago, Gajic Ognjen, Kashyap Rahul, Walkey Allan J
The Pulmonary Center, Division of Pulmonary, Allergy, Sleep and Critical Care, Department of Medicine, Boston University School of Medicine, Boston, MA.
Biostatistics and Epidemiology Data Analytics Center, Boston University School of Public Health, Boston, MA.
Crit Care Explor. 2022 Feb 18;10(2):e0638. doi: 10.1097/CCE.0000000000000638. eCollection 2022 Feb.
To describe hospital variation in use of "guideline-based care" for acute respiratory distress syndrome (ARDS) due to COVID-19.
Retrospective, observational study.
The Society of Critical Care Medicine's Discovery Viral Infection and
Adult patients with ARDS due to COVID-19 between February 15, 2020, and April 12, 2021.
Hospital-level use of "guideline-based care" for ARDS including low-tidal-volume ventilation, plateau pressure less than 30 cm HO, and prone ventilation for a Pao/Fio ratio less than 100.
Among 1,495 adults with COVID-19 ARDS receiving care across 42 hospitals, 50.4% ever received care consistent with ARDS clinical practice guidelines. After adjusting for patient demographics and severity of illness, hospital characteristics, and pandemic timing, hospital of admission contributed to 14% of the risk-adjusted variation in "guideline-based care." A patient treated at a randomly selected hospital with higher use of guideline-based care had a median odds ratio of 2.0 (95% CI, 1.1-3.4) for receipt of "guideline-based care" compared with a patient receiving treatment at a randomly selected hospital with low use of recommended therapies. Median-adjusted inhospital mortality was 53% (interquartile range, 47-62%), with a nonsignificantly decreased risk of mortality for patients admitted to hospitals in the highest use "guideline-based care" quartile (49%) compared with the lowest use quartile (60%) (odds ratio, 0.7; 95% CI, 0.3-1.9; = 0.49).
During the first year of the COVID-19 pandemic, only half of patients received "guideline-based care" for ARDS management, with wide practice variation across hospitals. Strategies that improve adherence to recommended ARDS management strategies are needed.
描述因新型冠状病毒肺炎(COVID-19)导致的急性呼吸窘迫综合征(ARDS)患者在接受“基于指南的治疗”方面的医院差异。
回顾性观察研究。
危重病医学会的发现病毒感染研究。
2020年2月15日至2021年4月12日期间因COVID-19导致ARDS的成年患者。
医院层面针对ARDS的“基于指南的治疗”,包括低潮气量通气、平台压小于30 cm H₂O以及对于氧合指数(Pao/Fio)小于100的患者采用俯卧位通气。
在42家医院接受治疗的1495例COVID-19 ARDS成年患者中,50.4%的患者曾接受过符合ARDS临床实践指南的治疗。在对患者人口统计学特征、疾病严重程度、医院特征以及疫情时间进行调整后,入院医院导致了“基于指南的治疗”中14%的风险调整后差异。与在随机选择的低使用推荐疗法医院接受治疗的患者相比,在随机选择的高使用基于指南治疗的医院接受治疗的患者接受“基于指南的治疗”的中位比值比为2.0(95%置信区间,1.1 - 3.4)。调整后的院内死亡率中位数为53%(四分位间距,47 - 62%),与最低使用“基于指南的治疗”四分位数组(60%)相比,最高使用“基于指南的治疗”四分位数组(49%)的患者死亡率风险有非显著降低(比值比,0.7;95%置信区间,0.3 - 1.9;P = 0.49)。
在COVID-19大流行的第一年期间,只有一半的患者在ARDS管理中接受了“基于指南的治疗”,各医院之间的实践差异很大。需要采取策略来提高对推荐的ARDS管理策略的依从性。